Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 1. Annual reported cases of notifiable diseases and rates* per 100,000, United States, excluding U.S. Territories and Non-U.S. Residents, 2022
Disease Case Count Rate
Anthrax — —
Arboviral diseases
Chikungunya virus disease 81 0.02
Eastern equine encephalitis virus disease
Neuroinvasive 1 0.00
Non-neuroinvasive — —
Jamestown Canyon virus disease
Neuroinvasive 11 0.00
Non-neuroinvasive 1 0.00
La Crosse virus disease
Neuroinvasive 19 0.01
Non-neuroinvasive 3 0.00
Powassan virus disease
Neuroinvasive 42 0.01
Non-neuroinvasive 4 0.00
St. Louis encephalitis virus disease
Neuroinvasive 28 0.01
Non-neuroinvasive 6 0.00
West Nile virus disease
Neuroinvasive 828 0.25
Non-neuroinvasive 310 0.09
Western equine encephalitis virus disease
Neuroinvasive — —
Non-neuroinvasive — —
Babesiosis
Total 2,111 0.74
Confirmed 1,812 0.63
Probable 299 0.10
Botulism
Total 197 0.06
Foodborne 6 0.00
Infant 163 4.43
Other (wound & unspecified) 28 0.01
Brucellosis 126 0.04
Campylobacteriosis 66,613 19.99
Candida auris, clinical † 1,001 0.37
Carbapenemase-producing carbapenem-resistant Enterobacteriaceae 2,818 1.08
Chancroid 1 0.00
Chlamydia trachomatis infection § 1,649,584 494.94
Cholera 12 0.00
Coccidioidomycosis 17,612 12.50
Coronavirus Disease 2019 (COVID-19)
Total 43,132,795 12,941.62
Confirmed 34,277,404 10,284.63
Probable  8,855,391 2,656.98
Cryptosporidiosis
Total 12,606 3.78
Confirmed 10,169 3.05
Probable 2,437 0.73
Cyclosporiasis 3,091 1.00
Dengue virus infections **
Dengue 1,454 0.44
Dengue-like illness 33 0.01
Severe dengue 43 0.01
Diphtheria 1 0.00
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 5,651 1.76
Ehrlichia chaffeensis infection 1,569 0.49
Ehrlichia ewingii infection 25 0.01
Undetermined ehrlichiosis/anaplasmosis 95 0.03
Giardiasis 13,819 5.21
Gonorrhea 648,010 194.43
Haemophilus influenzae, invasive disease
All ages, all serotypes 5,336 1.60
Age <5 years
Serotype b 17 0.09
Non-b serotype 140 0.76
Nontypeable 254 1.37
Unknown serotype 273 0.08
Hansen's disease 62 0.02
Hantavirus infection, non-hantavirus pulmonary syndrome †† — —
Hantavirus pulmonary syndrome 11 0.00
Hemolytic uremic syndrome post-diarrheal 312 0.10
Hepatitis, Viral Disease §§
Hepatitis A 2,264 0.68
Hepatitis B
Acute 2,126 0.64
Perinatal infection 13 NC
Hepatitis C
Acute 5,628 1.73
Confirmed 4,848 1.49
Probable 780 0.24
Perinatal infection 197 NC
Human immunodeficiency virus diagnoses 37,663 11.30
Influenza-associated pediatric mortality 116 0.16
Invasive pneumococcal disease ¶¶
All ages 18,362 7.35
Confirmed 17,916 7.17
Probable 446 0.18
Age <5 years 1,117 0.42
Confirmed 1,078 7.19
Probable 39 0.26
Legionellosis 7,512 2.25
Leptospirosis 62 0.02
Listeriosis ***
Total 963 0.29
Confirmed 902 0.27
Probable 61 0.02
Lyme disease †††
Total 62,428 18.81
Confirmed 2,066 0.62
Probable 60,362 18.19
Malaria 1,932 0.59
Measles §§§
Total 121 0.04
Indigenous 98 0.03
Imported 23 0.01
Meningococcal disease
All serogroups 312 0.09
Serogroups ACWY 168 0.05
Serogroup B 47 0.01
Other serogroups 20 0.01
Unknown serogroup 77 0.02
Mpox ¶¶¶ 29,821 8.95
Mumps 386 0.12
Novel Influenza A virus infections 12 0.00
Pertussis 3,044 0.91
Plague **** — —
Poliomyelitis, paralytic 1 0.00
Poliovirus infection, nonparalytic — —
Psittacosis 7 0.00
Q fever
Total 194 0.06
Acute 171 0.05
Chronic 23 0.01
Rabies
Animal 3,558 1.07
Human — —
Rubella 7 0.00
Rubella, congenital syndrome — —
Salmonella Paratyphi infection †††† 130 0.04
Salmonella Typhi infection §§§§ 442 0.13
Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) ¶¶¶¶ 56,129 16.84
Severe acute respiratory syndrome-associated coronavirus disease — —
Shiga toxin-producing Escherichia coli (STEC) 16,406 4.92
Shigellosis 14,744 4.42
Smallpox — —
Spotted fever rickettsiosis
Total 1,292 0.39
Confirmed 47 0.01
Probable 1,245 0.38
Streptococcal toxic shock syndrome 333 0.16
Syphilis
Total, all stages ***** 207,223 62.18
Congenital ††††† 3,755 100.20
Primary and secondary 59,010 17.71
Tetanus 26 0.01
Toxic shock syndrome (other than Streptococcal) 31 0.01
Trichinellosis 9 0.00
Tuberculosis 8,331 2.50
Tularemia 167 0.05
Vancomycin-intermediate Staphylococcus aureus 82 0.03
Vancomycin-resistant Staphylococcus aureus §§§§§ 2 0.00
Varicella morbidity 4,348 1.57
Varicella mortality 3 0.00
Vibriosis
Total 3,038 0.93
Confirmed 1,474 0.45
Probable 1,564 0.48
Viral hemorrhagic fevers
Chapare virus ¶¶¶¶¶ — —
Crimean-Congo hemorrhagic fever virus ****** — —
Ebola virus ****** — —
Guanarito virus ****** — —
Junin virus ****** — —
Lassa virus ****** — —
Lujo virus ****** — —
Machupo virus ****** — —
Marburg virus ****** — —
Sabia virus ****** — —
Yellow fever — —
Zika virus
Zika virus disease, congenital †††††† 1 0.03
Zika virus disease, non-congenital 5 0.00
Zika virus infection, congenital †††††† — —
Zika virus infection, non-congenital 2 0.00
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • NC: Not Calculated — There is insufficient data available to support this statistic.
  • * For population data, see Table 8. Also see Notes #3 and #7.
  • † Note that Candida auris colonization/screening cases are not included in this table. Additionally, there may be case count discrepancies of Candida auris clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for Candida auris case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.
  • § Beginning in January 2022, only confirmed cases are published to align with the approved CSTE position statement 21-ID-06, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years.
  • ¶ Of the reporting areas that submitted 2022 aggregate COVID-19 data to CDC, three did not submit probable cases. American Samoa, New York (excluding New York City), and U.S. Virgin Islands did not collect probable cases.
  • ** Counts include confirmed and probable dengue cases.
  • †† Case counts may include Old World hantavirus infections, such as Seoul virus.
  • §§ Chronic hepatitis B and chronic hepatitis C data are not included in NNDSS tables but reported case counts are included in the annual Viral Hepatitis Surveillance Report, 2022, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • ¶¶ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • *** Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately.
  • ††† For surveillance reporting purposes, jurisdictions are grouped into high- and low-incidence categories. Confirmed cases are only reported from low-incidence jurisdictions; however, probable cases are reported from both high- and low-incidence jurisdictions. For more information on jurisdiction classifications, visit https://www.cdc.gov/lyme. Currently, high-incidence jurisdictions include Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York (excluding New York City), New York City, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, Wisconsin, and the District of Columbia.
  • §§§ Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
  • ¶¶¶ CSTE adopted Mpox as a nationally notifiable condition on June 23, 2022 and beginning August 1, 2022 confirmed and probable cases are published to align with the CSTE position statement 22-ID-10. Case classifications for cases reported prior to August 1, 2022 should not have been retroactively changed based on the case definition in the CSTE position statement 22-ID-10.
  • **** Beginning in 2020, confirmed and probable plague cases began to be combined and published.
  • †††† Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • §§§§ Beginning in January 2019, cases began to be reported as Salmonella Typhi infection. In previous years, cases were reported as typhoid fever.
  • ¶¶¶¶ Beginning in January 2019, cases began to be reported as salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • ***** Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations) and congenital syphilis.
  • ††††† Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth.
  • §§§§§ Vancomycin-resistant Staphylococcus aureus cases reported in this table may not have been verified by CDC. CDC verified 0 vancomycin-resistant Staphylococcus aureus cases in 2022.
  • ¶¶¶¶¶ Beginning in January 2022, Chapare virus was added as a nationally notifiable condition, and confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04.
  • ****** Beginning in January 2022, confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04, whereas in previous years, only confirmed cases were published.
  • †††††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2022 annual tables were officially closed on March 29, 2024.
  2. The list of national notifiable Infectious diseases and conditions for 2022 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2022" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2022 data are available at https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2022 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2022, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2022" population estimates for years 2020-2022 were released March 2024 by the National Cancer Institute at https://seer.cancer.gov/popdata/. For more information, see https://seer.cancer.gov/popdata/singleages.html Population estimates for territories are the 2022 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on May 02, 2024, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Genre" box on the left-hand side and select "Annual Reports".
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction is ≤24 months)
    • Perinatal hepatitis C infection (age restriction is ≤36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2022 (National Center for Health Statistics Natality 2022, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. Disease data presented in the 2022 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.